共查询到10条相似文献,搜索用时 79 毫秒
1.
2.
目的:研究转酮醇酶样基因1(tktl1)在肝细胞肝癌(HCC)中的表达及其与临床病理的关系。方法:RT-PCR法检测转酮醇酶基因家族各成员(tkt、tktl1、tktl2)mRNA在42例HCC及癌旁组织中的表达并研究其与临床病理参数间的关系。结果:HCC组织中tktl1阳性表达率明显高于tkt和tktl2的阳性表达率(P〈0.05)。tktl1在HCC中的阳性表达率明显高于癌旁组织(P〈0.05);而tkt和tktl2阳性表达率在肝癌及癌旁组织间无明显差异(P〉0.05)。 HCC中tktl1的高表达同肿瘤分化程度,静脉癌栓,CLIP评分有关(P〈0.05),而与性别、年龄、肿瘤大小、肝内及淋巴转移、AFP水平无关(P〉0.05)。结论:tktl1与HCC的发生发展有关,影响肝癌的分化、转移及患者预后,有望成为HCC治疗的新靶点。 相似文献
3.
目的:研究转酮醇酶样基因1(tktl1)在肝细胞肝癌(HCC)中的表达及其与临床病理的关系.方法:RT-PCR法检测转酮醇酶基因家族各成员(tkt、tktl1、tktl2)mRNA在42例HCC及癌旁组织中的表达并研究其与临床病理参数间的关系.结果:HCC组织中tktl1 阳性表达率明显高于tkt和tktl2的阳性表达率 (P<0.05).tktl1在HCC中的阳性表达率明显高于癌旁组织(P<0.05);而 tkt和tktl2阳性表达率在肝癌及癌旁组织间无明显差异(P>0.05). HCC中tktl1的高表达同肿瘤分化程度,静脉癌栓,CLIP评分有关 (P<0.05),而与性别、年龄、肿瘤大小、肝内及淋巴转移、AFP水平无关(P>0.05).结论:tktl1与HCC的发生发展有关,影响肝癌的分化、转移及患者预后,有望成为HCC治疗的新靶点. 相似文献
4.
Hepatitis B virus (HBV) is a human pathogen that has infected an estimated two billion people worldwide. Despite the availability of highly efficacious vaccines, universal screening of the blood supply for virus, and potent direct acting anti-viral drugs, there are more than 250 million carriers of HBV who are at risk for the sequential development of hepatitis, fibrosis, cirrhosis and hepatocellular carcinoma (HCC). More than 800,000 deaths per year are attributed to chronic hepatitis B. Many different therapeutic approaches have been developed to block virus replication, and although effective, none are curative. These treatments have little or no impact upon the portions of integrated HBV DNA, which often encode the virus regulatory protein, HBx. Although given little attention, HBx is an important therapeutic target because it contributes importantly to (a) HBV replication, (b) in protecting infected cells from immune mediated destruction during chronic infection, and (c) in the development of HCC. Thus, the development of therapies targeting HBx, combined with other established therapies, will provide a functional cure that will target virus replication and further reduce or eliminate both the morbidity and mortality associated with chronic liver disease and HCC. Simultaneous targeting of all these characteristics underscores the importance of developing therapies against HBx. 相似文献
5.
目的:研究WFDC1基因在肝癌组织和细胞中的表达变化,探讨其与肝癌临床病理指标及生存预后之间的关系,为肝癌的诊断以及预后判断提供参考依据。方法:采用qPCR法分别检测肝癌患者的肿瘤组织和癌旁组织、MC-LR诱导的人肝细胞L02恶性转化细胞和肝癌细胞株SMMC-7721、HepG2、Hep3B、Huh-7中WFDC1 mRNA的表达水平。基于TCGA数据库,分析WFDC1基因在肝癌患者肿瘤组织(331例)和癌旁组织(50例)中的表达及其与临床病理指标和生存预后的关系。结果:qPCR检测结果表明,与癌旁组织比较,WFDC1 mRNA在肝癌组织、MC-LR诱导的L02恶性转化细胞以及肝癌细胞中的表达均显著下调(P < 0.05)。TCGA数据库中WFDC1 mRNA表达分析也表明,肝癌组织的表达显著低于癌旁组织(P < 0.01),且WFDC1 mRNA的表达下调与肿瘤分级和临床分期高度相关(P < 0.05)。Kaplan-Meier分析表明,WFDC1 mRNA高表达患者生存时间高于低表达患者(Log-rank=4.80,P < 0.05)。ROC曲线分析结果表明,WFDC1 mRNA是一个特异度和灵敏度较好的肝癌诊断指标(AUC=0.829)。结论:WFDC1基因可能是一个抑癌基因,检测该基因的表达水平对肝癌患者的诊断和预后判断具有参考价值。 相似文献
6.
小肝细胞癌患者染色体1p36杂合性缺失的特点 总被引:1,自引:0,他引:1
目的: 探讨人类染色体1p36等位基因杂合性缺失在小肝细胞癌(small hepatocellular carcinoma, sHCC)发生发展中的作用及其与临床病理表现的关系。方法:采用PCR非变性聚丙烯酰胺凝胶电泳和硝酸银染色技术,对140例信息性sHCC中1p36上9个多态性微卫星标志位点的杂合性缺失(lo 相似文献
7.
Potent antitumor efficacy of an E1B 55kDa-deficient adenovirus carrying murine endostatin in hepatocellular carcinoma 总被引:3,自引:0,他引:3
Li G Sham J Yang J Su C Xue H Chua D Sun L Zhang Q Cui Z Wu M Qian Q 《International journal of cancer. Journal international du cancer》2005,113(4):640-648
Data from clinical trails have shown that the antitumoral effect of ONYX-015, an E1B 55kDa-deficient adenovirus, as monotherapy is insufficient. To enhance its efficiency, CNHK200-mE, another E1B 55kDa-deficient adenovirus armed with a mouse endostatin gene was constructed and its antitumoral activities against hepatocellular carcinoma (HCC) in vitro and in vivo were investigated. The selective replication and cytotoxicity of CNHK200-mE in Hep3B and HepGII cells independent of p53 status were confirmed via TCID50 and 3-(4,5dimetylthiazol)-2,5-diphenyltetrazolium bromide (MTT) assays. Potent tumor growth suppression on SMMC-7721 xenografts in nude mice was observed and a synergistic effect of the carrier virus and the therapeutic gene was suggested. Moreover, in comparison with the nonreplicative adenovirus carrying the same therapeutic gene, amplified transgene expression of mouse endostatin in vitro and in vivo were confirmed by Western blotting and ELISA assay. The effective angiogenesis inhibition and replication of CNHK200-mE in nude mice xenografts were demonstrated by immunohistochemistry. In conclusion, the recombinant adenovirus CNHK200-mE is a replication-competent oncolytic virus mediating high expression of therapeutic gene. Because CNHK200-mE is capable of replicating in and lysing HCC cells selectively with effective tumor growth suppression and antiangiogenic activity on HCC xenografts in nude mice, it holds good potential for the treatment of HCC. 相似文献
8.
9.
腺相关病毒介导的HGFK1对大鼠肝细胞癌的治疗作用研究 总被引:2,自引:1,他引:1
背景与目的:肝细胞痛是一种有高度新生血管的肝脏恶性肿瘤,进展期肝细胞癌的预后很差,目前缺乏有效的治疗.近来有报道肝细胞生长因子的Kringle 1结构域(HGFK1)基因具有很强的抑制新生血管的作用.本研究探讨肝细胞生长因子Kringle 1结构域(HGFK1)基因对原发性肝细胞癌的治疗作用及其机制.方法:构建携带有HGFK1基因的腺相关病毒载体(rAAV-HGFK1),建立大鼠原发性肝细胞癌模型,以rAAV-HGFK1进行治疗,继而观察大鼠原发性肝癌模型的生存时间、肿瘤生长情况、肿瘤内血管密度以及转移情况.结果:在大鼠肝脏内注射6×105个大鼠肝细胞癌细胞株McA-RH7777后,第10天全部成瘤.通过向瘤内和门静脉内注射rAAV-HGFK1导入HGFK1基因可以明显延长荷肝细胞癌大鼠的生存时间,对照组生存时间为30 d,而治疗组的生存时间为49 d.在对照的PBS注射组和AAV-EGFP注射组,肝脏和腹腔内转移的发生率都是100%;而肺转移的发生率则分别为100%和83%.而治疗组都没有转移,且腹水的发生率才只有33%.组织学证实AAV-HGFK1对肿瘤的作用则具体表现为肿瘤生长的受到抑制、肿瘤内血管密度的减少、以及发生肝内、肺、腹膜等转移机率的下降.HGFK1表现出了明显的抗血管生成及抑制肿瘤细胞生长作用.在大鼠体内的毒性实验未发现明显毒性.结论:HGFK1能通过抗血管生成作用达到抑制肝细胞癌原发灶及转移灶的效果,显著延长荷瘤大鼠的生存时间,没有发现明显的毒性,为临床抗肿瘤治疗提供了一个潜在的新靶点. 相似文献